Exhibit 10.30

                             CONSULTING AGREEMENT

      This  AGREEMENT  ("Agreement"),  dated as of June 1, 2007, is made by and
between Duska Therapeutics, Inc. a Nevada  corporation with its principal place
of business at Two Bala Plaza, Suite 300, Bala  Cynwyd, Pennsylvania 19004 (the
"Company"), and James S. Kuo, M.D., M.B.A. of 1050  Scarlati  Place,  La Jolla,
California 92037 ("Consultant").

      WHEREAS,  the  Company  is  seeking  to  raise  capital  through  private
placement  of  units  (the "Units") with each unit consisting of one shares  of
common stock of the Company  (the  "Common  Stock") and one warrant to purchase
one share of common stock of the Company; and

      WHEREAS, the Company desires to engage  Consultant  as its representative
in  meetings  with  accredited  investors (as such term is defined  under  Rule
501(a) of Regulation D issued by  the  Securities and Exchange Commission under
the Securities Act of 1933) and who may  be interested in purchasing Units from
the  Company  (each  a  "Potential  Investor",   and  collectively,  "Potential
Investors"); and

      WHEREAS, Consultant desires to be engaged by  the  Company  on  the terms
provided herein;

      NOW, THEREFORE, the Company and Consultant agree as follows:

      1.    DUTIES.   Consultant  agrees  to discuss the Company with Potential
Investors and, in connection therewith to describe the business of the Company,
it prospects and its value proposition.  Consultant  shall have no authority to
execute any documents on behalf of the Company, to bind  the Company in any way
on  any matter or to hold himself out to any Potential Investor  or  any  other
person  as  being  a representative of the Company.  The Consultant will not be
responsible for any  outcome  or  damage  to  the  Company  as  a result of the
Company's  present  or future contact with any Potential Investor.   Consultant
will devote as much of  his  time  to  his duties hereunder as Consultant deems
necessary to perform such services.

      2.    TERM.  This Agreement shall commence upon the date hereof and shall
continue for a term that ends on the sooner  of July 31, 2007 or the closing of
the private placement (the "Closing"), unless extended by mutual consent of the
parties.   Either  party  may  terminate  this Agreement  upon  written  notice
delivered to the other party at least ten (10) business days prior to effective
date of such termination.

      1.    COMPENSATION.   Promptly after the  execution  of  this  Agreement,
            Consultant will be awarded 10,000 options to purchase 10,000 shares
            of Common Stock at  an  exercise  price  of  $0.50  per  share (the
            "Options").   If the Closing occurs after June 30, 2007 and  before
            July 31, 2007,  Consultant  shall  receive  an additional number of
            Options  determined by multiplying 10,000 by the  quotient  of  the
            number of  days  up  to  and including the Closing and 31.  For the
            sake of clarity the formula is:

                                       1
<PAGE>


     Number of Options granted
     during July if the Closing       =     10,000 x (Number of days up to and
     including                              closing/31)
     occurs in July

If the Closing does not occur before July  31, 2007, Consultant will be awarded
an additional 10,000 Options on July 31, 2007.

      2.    REIMBURSEMENT.   The Company will  reimburse  Consultant  with  all
            accountable travel,  entertainment,  and any out-of-pocket expenses
            of Consultant incurred pursuant to this Agreement.

      5.    TAXES.  Consultant is responsible for  paying any federal, state or
local taxes on the consulting services provided under this Agreement.

      6.    INDEPENDENT  CONTRACTOR.   At all times during  the  term  of  this
Agreement, Consultant is and shall be an  independent contractor, with the sole
right  to  supervise,  manage, operate, control,  and  direct  the  performance
incident to the services.   Nothing contained in this Agreement shall be deemed
or  construed  to  create  a  partnership  or  joint  venture,  to  create  the
relationship of employee/employer  or  principal/agent, or otherwise create any
liability whatsoever as partner, joint venturer, employer, employee, principal,
or agent for either the Company or Consultant with respect to the indebtedness,
liabilities, or obligations of each other or of any other person or entity.

      7.    CONFIDENTIALITY.  As a condition  to this Agreement and the payment
of any fees under Section 3 hereof, Consultant  has  executed  and delivered to
the Company a Confidentiality Agreement in the form attached hereto  as Exhibit
A (the "CDA").  The CDA shall survive the term of this Agreement or any earlier
termination  hereof.  In the absence of a separately signed CDA, the Consultant
agrees that the  terms  and  provisions  of  the CDA are incorporated into this
Agreement  and  that  Consultant's  signature  herein   also   constitutes  the
Consultant's acceptance of the terms of the CDA.

      8.    INDEMNIFICATION.   The  Company agrees to indemnify the  Consultant
against any and all losses, claims, damages  or  liabilities ("Damages") of any
kind to which Consultant becomes subject directly  or  indirectly related to or
arising in connection with the performance by Consultant of services hereunder,
unless such Damages arose out of Consultant's negligence  or willful misconduct
of  Consultant  in  connection  with the performance of his duties  under  this
Agreement.

      9.    MISCELLANEOUS.

            (a)   This Agreement may not be assigned by the Company without the
 written consent of the Consultant,  except  that the Company shall assign this
 Agreement to any entity to which it conveys substantially all of its assets or
 into which it is merged or consolidated.  The  Consultant  may not assign this
 Agreement.




                                       2
<PAGE>


            (b)   This Agreement shall be construed and enforced  in accordance
with, and the rights of the parties shall be governed by, the laws of the State
of  Pennsylvania,  without  giving  effect  to  the  conflict of law provisions
thereof.

            (c)   This Agreement shall be binding upon  and inure solely to the
benefit of the parties hereto, and no other person shall  have  or be construed
to have any legal or equitable right, remedy or claim under or in respect of or
by  virtue  of  this  Agreement  or any provisions herein contained, except  as
otherwise stated herein.

            (d)   Notices hereunder shall be deemed made if given by registered
or certified mail with postage prepaid  and  addressed  to the party to receive
such  notice at the address given above or as may hereafter  be  designated  by
notice.

            (e)   This   Agreement  (including  any  Exhibits  hereto  and  the
documents delivered pursuant  hereto)  constitutes  the entire agreement of the
parties  hereto with respect to the subject matter hereof  and  supersedes  all
prior agreements  and  undertakings,  both  written and oral, among the parties
hereto with respect to the subject matter.

            (f)   If any term or other provision  of  this  Agreement  (or  any
Exhibit  hereto)  is  invalid, illegal or incapable of being enforced under any
law or public policy, all  other  terms  and  provisions of this Agreement will
nevertheless remain in full force and effect.  Upon such determination that any
term or other provision is invalid, illegal or incapable of being enforced, the
parties hereto will negotiate in good faith to  modify  this Agreement so as to
effect  the  original  intent  of  the  parties  as closely as possible  in  an
acceptable manner.  It is expressly understood and agreed that the restrictions
contained  in  this Agreement are reasonable and necessary  to  protect  Duska.
Accordingly,  if  a  final  judicial  determination  is  made  that  the  time,
territory, scope  or  any  other  restriction  contained  in  this Agreement is
unreasonable or otherwise unenforceable, this Agreement shall not  be  rendered
void,  but shall be deemed amended to apply as to such maximum scope, time  and
territory  and  to  such other extent as such court may judicially determine or
indicate to be reasonable, or if the court or other governmental authority does
not so determine or indicate, to the maximum extent which any pertinent statute
or judicial decision  may  indicate  to  be  a reasonable restriction under the
circumstances  involved,  as  so modified, the restrictions  contains  in  this
Agreement shall be binding and enforceable.

            (a)   Except as expressly  provided  herein, neither this Agreement
                  nor  any term hereof may be amended,  waived,  discharged  or
                  terminated  other  than by a written instrument signed by the
                  party against whom enforcement of any such amendment, waiver,
                  discharge or termination is sought.

            (h)   Whenever the context may require,  any  pronouns  used herein
shall  include  the  corresponding masculine, feminine or neuter forms and  the
singular forms on the  nouns  and  pronouns  shall  include the plural and vice
versa.


                                       3
<PAGE>

            (i)   The  section headings are used solely  for  convenience,  and
shall not affect the construction thereof.

            (j)   This Agreement  may  be  executed  in  a  number of identical
counterparts, each of which, for all purposes, is to be deemed an original, and
all of which constitute, collectively, one agreement; but in  making  proof  of
this  Agreement,  it shall not be necessary to produce or account for more than
one such counterpart.

IN WITNESS WHEREOF,  this  Agreement  has  been  executed  by  the  Company and
Consultant as of the date first written above.


                                                DUSKA THERAPEUTICS, INC.


                                              By:   /s/ Amir Pelleg, Ph.D.
                                              -----------------------------
                                                  Name: Amir Pelleg, Ph.D.
                                                 Title: President and COO


                                                JAMES S. KUO, M.D., M.B.A.


                                                   /s/   JAMES S. KUO, M.D.
                                                   -------------------------



                                       4
<PAGE>



                           CONFIDENTIALITY AGREEMENT


This Confidentiality Agreement (the "Agreement") is made this 1st  day  of June
2007, by and between Duska Therapeutics, Inc., whose address is Two Bala Plaza,
Suite 300, Bala Cynwyd, PA 19004 ("Duska", hereunder), and James S. Kuo,  M.D.,
M.B.A. of 1050 Scarlati Place, La Jolla, California 92037 ("Kuo", hereunder).



BACKGROUND:

      A.    Duska   has   certain  confidential  and  proprietary  information,
            including  but not  limited  to  inventions,  patent  applications,
            patents, data, information, methods, processes, know how, and ideas
            relating to  purinergic receptors, adenosine 5'-triphosphate (ATP),
            adenosine, cardio-cardiac and pulmonary-pulmonary reflexes, allergy
            and asthma and  related  disorders,  male  infertility and in vitro
            fertilization  and  related  scientific  and  business  information
            ("Information").

      B.    Kuo has an extensive experience and expertise in all aspects of the
            pharmaceutical  industry including management, financing  and  drug
            development.

      C.    Duska is desirous  of  disclosing  Information to Kuo in connection
            with its consideration of appointing Kuo as its President and Chief
            Executive  Officer,  and  Kuo's  is desirous  of  considering  this
            appointment.

      NOW THEREFORE, intending to be legally bound, the parties agree as
follows:

      1.    Duska  may,  in  its discretion, disclose  to  Kuo  Information  in
writing  or  verbally.   Information  disclosed  in  writing  will  be  labeled
CONFIDENTIAL, and verbal Information  will be submitted within two weeks of its
disclosure  in a succinct written form labeled  CONFIDENTIAL.   Kuo  agrees  to
receive and maintain  in  strict confidence all Information received from Duska
whether in writing or verbally.  Kuo agrees not to disclose such Information to
any third party.  Kuo agrees not to use any such Information except to evaluate
and analyze the Information  in determining if he will enter into a contractual
relationship with Duska.

      2.    Kuo agrees to treat  Information  as  strictly  confidential and to
take all necessary precautions to prevent the disclosure of such Information to
others.  Kuo agrees to notify Duska in the event that Kuo has reason to believe
that any third party, firm or corporation has or may have access to Information
when such access has not been authorized by Duska.  Kuo agrees that Information
will be reviewed by the least possible number of people necessary  to  evaluate
Information and only by those employed by Kuo who have secrecy agreements  with
Kuo.   Such  review  shall  be completed as promptly as possible.  Upon Duska's
request, Kuo will promptly return to Duska all Information provided by Duska to
Kuo under this Agreement except  as required by law.  The return of Information
will not relieve Kuo of its continuing obligation of confidentiality hereunder.

                                       1
<PAGE>

      3.    The foregoing restrictions on the use and disclosure shall not
apply to any such Information which:

            a.    at  the time of disclosure,  was  already  known  to  Kuo  as
                  evidenced in writing;

            b.    at the  time  of  disclosure,  is  generally available to the
                  public or subsequently becomes available  to the public other
                  than by an act or omission on Kuo's part;

            c.    shall be made available to Kuo on a non-confidential basis by
                  a third party having the lawful right to do so; or

            d.    is  required to be disclosed pursuant to legal,  judicial  or
                  administrative  proceedings,  in  which  event Kuo shall give
                  Duska as much advance notice as reasonably  possible  of such
                  required disclosure.

      4.    Nothing  contained  herein  shall  be  construed  as giving Kuo any
rights or license in or with respect to any of Information, except the right to
review,  analyze  and  evaluate Information on behalf of Duska.  Neither  party
shall have any obligation  to  enter  into  any  investment  banking  or  other
commercial relationship as a result of entering into this Agreement.

      5.    This  Agreement  supersedes all prior understandings and agreements
between the parties hereto, whether  oral  or  written,  with  respect  to  the
subject matter hereof.  To be effective, an amendment, waiver or termination of
this  Agreement  or  any of its provisions must be in a document signed by each
party which specifically  states  that  it amends, waives or terminates, as the
case may be, this Agreement or such provision.

      6.    The obligations imposed on Kuo  hereunder  shall  continue in force
until such Information enters into the public domain or after three  years from
the date of execution of this Agreement, whichever come first.

      7.    This Agreement shall be governed by the laws of the Commonwealth of
Pennsylvania  and  enforceable  in  any court of competent jurisdiction in  the
Commonwealth  of  Pennsylvania.  Kuo hereby  submits  to  the  jurisdiction  of
Pennsylvania courts  and waives any objections it may have to such jurisdiction
for controversies arising under this Agreement.


                                       2
<PAGE>

      8.    It is expressly understood and agreed that the restrictions
contained in this Agreement are reasonable and necessary to protect Duska.
Accordingly, if a final judicial determination is made that the time,
territory, scope or any other restriction contained in this Agreement is
unreasonable or otherwise unenforceable, this Agreement shall not be rendered
void, but shall be deemed amended to apply as to such maximum scope, time and
territory and to such other extent as such court may judicially determine or
indicate to be reasonable, or if the court or other governmental authority does
not so determine or indicate, to the maximum extent which any pertinent statute
or judicial decision may indicate to be a reasonable restriction under the
circumstances involved, as so modified, the restrictions contains in this
Agreement shall be binding and enforceable.  In the event any one or more of
the provisions of this Agreement is invalid or otherwise unenforceable, the
enforceability of remaining provisions shall be unimpaired.

      9.    This Agreement shall not be assigned or transferred by Kuo.

      10.   Kuo acknowledges  that the restrictions contained in this Agreement
are in view of the nature of Information  reasonable  and  necessary to protect
the  legitimate  proprietary  interests  of  Duska and that any breach  of  any
provision of this Agreement by Kuo could result  in substantial and irreparable
harm  to  Duska.   Accordingly,  Kuo  agrees that damages  at  law  may  be  an
inadequate remedy for breach of this Agreement and that Duska shall be entitled
to seek injunctive relief, enjoining and  restraining  Kuo  from  disclosing or
using  any such Information and specific performance, without the necessity  of
proving  actual  damages  for  any  such  breach.  The rights set forth in this
Section shall be in addition to all other rights  Duska  may  have at law or in
equity.

      IN  WITNESS  WHEREOF,  the parties, intending to be legally  bound,  have
caused this Agreement to be executed  by  their duly authorized representatives
on the date indicated below.


JAMES S. KUO, M.D., M.B.A.


/s/ James S. Kuo, M.D.
--------------------------

Date:  June 1, 2007


DUSKA THERAPEUTICS, INC.


By: /s/  Amir Pelleg, Ph.D.
----------------------------
Name:    Amir Pelleg, Ph.D.
Title:   President and COO

Date:  June 1, 2007


                                       3
<PAGE>